High-risk groups are patients with a positive family history of PC, hereditary PC, familial atypical multiple mole melanoma (p16 mutation), cystic fibrosis, Peutz–Jeghers syndrome, Lynch syndrome and HBOC (BRCA1/BRCA2 mutation). Here, BRCA2 is linked to cystic fibrosis.